Loading...
Market
Story
Eli Lilly's Zepbound Shows 38% Reduction in Heart Failure Risk in Obesity-Related Phase 3 Trial with 700 Participants
Aug 1, 2024, 11:00 AM
Eli Lilly's weight-loss drug Zepbound has shown significant cardiovascular benefits in a recent late-stage study. The SUMMIT phase 3 trial, which involved over 700 participants, demonstrated that tirzepatide, the active ingredient in Zepbound, reduced the risk of heart failure outcomes by 38% compared to a placebo. The study also highlighted improvements in heart failure symptoms and physical limitations among patients with obesity-related heart failure and preserved ejection fraction. These findings mark the first trial to establish the long-term cardiovascular benefits of Zepbound, potentially positioning it as a leading treatment for patients with heart failure and obesity.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
1st • 25%
2nd • 25%
3rd • 25%
4th or lower • 25%
Zepbound gains >10% market share over Wegovy • 25%
Zepbound gains 0-10% market share over Wegovy • 25%
Wegovy maintains current market share • 25%
Wegovy gains market share over Zepbound • 25%
Less than 15% • 25%
15% to 20% • 25%
20% to 25% • 25%
More than 25% • 25%
Less than 20% • 25%
20% to 22% • 25%
22% to 24% • 25%
More than 24% • 25%